Literature DB >> 12924929

Percent free base nicotine in the tobacco smoke particulate matter of selected commercial and reference cigarettes.

James F Pankow1, Ameer D Tavakoli, Wentai Luo, Lorne M Isabelle.   

Abstract

The available evidence suggests that most of the nicotine in mainstream tobacco smoke is in the smoke particle matter (PM) phase. Nicotine can exist in protonated and free base forms in the smoke PM, and alpha(fb) is the fraction of the PM nicotine that is in the free base form. Because only the free base form can volatilize from the smoke PM phase to the gas phase of an inhaled aerosol and because gaseous nicotine deposits rapidly in the respiratory tract (RT), the magnitude and rate of nicotine deposition in the RT will depend on alpha(fb). The types of values that alpha(fb) can assume in the PM of cigarette smoke aerosols have not been well-known. The conventional view has been that mainstream cigarette smoke PM contains relatively little free base nicotine so that the cigarette smoker must absorb nicotine mostly from deposited particles. A prior study concluded that because cigarette smoke is at "pH 5.3", there is very little free base nicotine in such smoke. A 1994 internal tobacco company document discusses the view that "smoke pH" values for cigarette smoke are "approximately 6.0". This work uses volatility-based measurements to provide determinations of equilibrium nicotine alpha(fb) values for mainstream smoke PM from selected cigarettes. The effective pH (i.e., pH(eff)) of the smoke PM from selected brands of commercial cigarettes was found to span a range of 6.0-7.8 (nicotine alpha(fb) = 0.01-0.36), with all pH(eff) values much larger than 5.3 and most larger than 6.0.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12924929     DOI: 10.1021/tx0340596

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  20 in total

1.  Free-Base and Protonated Nicotine in Electronic Cigarette Liquids and Aerosols.

Authors:  Ahmad El-Hellani; Rachel El-Hage; Rima Baalbaki; Rola Salman; Soha Talih; Alan Shihadeh; Najat A Saliba
Journal:  Chem Res Toxicol       Date:  2015-07-22       Impact factor: 3.739

Review 2.  Consumer acceptable risk: how cigarette companies have responded to accusations that their products are defective.

Authors:  K Michael Cummings; Anthony Brown; Clifford E Douglas
Journal:  Tob Control       Date:  2006-12       Impact factor: 7.552

3.  Brand differences of free-base nicotine delivery in cigarette smoke: the view of the tobacco industry documents.

Authors:  G Ferris Wayne; G N Connolly; J E Henningfield
Journal:  Tob Control       Date:  2006-06       Impact factor: 7.552

Review 4.  Pharmacological and chemical effects of cigarette additives.

Authors:  Michael Rabinoff; Nicholas Caskey; Anthony Rissling; Candice Park
Journal:  Am J Public Health       Date:  2007-07-31       Impact factor: 9.308

5.  Determination of Nicotine Content and Delivery in Disposable Electronic Cigarettes Available in the United States by Gas Chromatography-Mass Spectrometry.

Authors:  Todd Pagano; A Gary DiFrancesco; Susan B Smith; Jerrin George; Gloria Wink; Irfan Rahman; Risa J Robinson
Journal:  Nicotine Tob Res       Date:  2015-06-04       Impact factor: 4.244

Review 6.  Pharmacokinetic Drug Interactions with Tobacco, Cannabinoids and Smoking Cessation Products.

Authors:  Gail D Anderson; Lingtak-Neander Chan
Journal:  Clin Pharmacokinet       Date:  2016-11       Impact factor: 6.447

7.  Developing a Rational Approach to Tobacco Use Treatment in Pulmonary Practice: A Review of the Biological Basis of Nicotine Addiction.

Authors:  Frank T Leone; Sarah Evers-Casey
Journal:  Clin Pulm Med       Date:  2012-03-01

8.  Nicotine delivery to rats via lung alveolar region-targeted aerosol technology produces blood pharmacokinetics resembling human smoking.

Authors:  Xuesi M Shao; Bin Xu; Jing Liang; Xinmin Simon Xie; Yifang Zhu; Jack L Feldman
Journal:  Nicotine Tob Res       Date:  2012-12-13       Impact factor: 4.244

9.  Nicotine delivery capabilities of smokeless tobacco products and implications for control of tobacco dependence in South Africa.

Authors:  O A Ayo-Yusuf; T J P Swart; W B Pickworth
Journal:  Tob Control       Date:  2004-06       Impact factor: 7.552

Review 10.  Monitoring the tobacco use epidemic II: The agent: Current and emerging tobacco products.

Authors:  Steven D Stellman; Mirjana V Djordjevic
Journal:  Prev Med       Date:  2008-09-20       Impact factor: 4.018

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.